Invivyd, Inc.
NASDAQ:IVVDBiotechnology
+$0.04 today
- Market cap
- $138.68M
- Beta
- 0.63
- P/E (TTM)
- -3.9
- EPS (TTM)
- -$0.25
Volume 6.71M
Average 3.62M
IVVD Other Income / Expenses
Net non-operating gains and losses, such as investment results, currency effects, and one-off items.
Invivyd, Inc.NASDAQ: IVVD
Other Income / Expenses · Q1 FY2026 · quarter ended Mar 2026
Other income / expenses growth accelerates
Q1 FY2026 other income / expenses of $1.74M rose 174.2% year over year, ahead of the -16.4% change in trailing-twelve-month other income / expenses. Sequentially, it rose 16.9% from the prior quarter. Over 3 fiscal years it compounded at -23.0% a year.
Context
- Other income / expenses amounted to 5.7% of revenue in FY2025, down 21.6 pp from a year earlier.
- Other income / expenses increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +174.2% holds above the trailing-twelve-month pace of -16.4%.
Sources:Income StatementText generated from reported figures; not investment advice.
Other Income / Expenses history
USD · from the income statement
- Latest · FY2025
- 3.07M USD
- Year-over-year change
- -55.8%
- 4-year CAGR
- +125.9%
| Period | Period end | Other Income / Expenses | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.07M | -55.8% |
| FY2024 | 2024-12-31 | 6.95M | -50.8% |
| FY2023 | 2023-12-31 | 14.12M | +110.2% |
| FY2022 | 2022-12-31 | 6.71M | +5589.8% |
| FY2021 | 2021-12-31 | 118K | — |
Other Income / Expenses vs competitors
How IVVD compares with its peers on the latest reported figures
- IVVD's LTM Mar 2026 other income / expenses of $4.17M is the 4th highest of the 10 companies compared; the peer median is $325K.
- Its year-over-year change of -16.4% is the 5th highest of 9, against a peer median of -6.0%.
- Other income / expenses amounts to 7.5% of revenue for IVVD, versus a peer median of 22.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $10.16M | -24.2% | — | 29.2% | |
| LTM Mar 2026 | $6.75M | +12.2% | +85.7% | — | |
| LTM Mar 2026 | $4.56M | +71.8% | +107.2% | 15.8% | |
| LTM Mar 2026 | $4.17M | -16.4% | -23.0% | 7.5% | |
| LTM Sep 2026 | $3.68M | +270.3% | +29.5% | — | |
| LTM Mar 2026 | $325K | -86.9% | — | 1.0% | |
| LTM Mar 2026 | -$5.24M | — | — | — | |
| LTM Mar 2026 | -$6.03M | +17.5% | — | 7.7% | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$6.67M | -1912.5% | — | 342.2% |
| LTM Mar 2026 | -$13.7M | -653.1% | — | 39.6% | |
| Peer median (excluding IVVD) | $325K | -6.0% | +85.7% | 22.5% | |
Competitors are the stored peer set for IVVD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 25.38M | 53.43M |
| Cost of Revenue | 0 | 0 | 0 | 1.62M | 3.75M |
| Gross Profit | 0 | 0 | 0 | 23.77M | 49.68M |
| Gross Margin | — | — | — | 93.6% | 93.0% |
| Research & Development | 182.89M | 179.21M | 158.66M | 137.25M | 38.31M |
| Selling, General & Admin | 36.52M | 47.04M | 49.13M | 63.39M | 66.93M |
| Operating Expenses | 226.91M | 248.03M | 212.76M | 200.64M | 105.24M |
| Depreciation & Amortization | 1K | 462K | 2.03M | 3.11M | 2.11M |
| EBITDA | (219.41M) | (225.8M) | (205.76M) | (166.81M) | (50.38M) |
| EBITDA Margin | — | — | — | -657.2% | -94.3% |
| Operating Income | (226.91M) | (248.03M) | (212.76M) | (176.88M) | (55.56M) |
| Operating Margin | — | — | — | -696.8% | -104.0% |
| Interest Income | 0 | 6.71M | 0 | 6.95M | 0 |
| Interest Expense | 0 | 43.08M | 0 | 0 | 0 |
| Other Income / Expenses | 118K | 6.71M | 14.12M | 6.95M | 3.07M |
| Income Before Tax | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Pre-Tax Margin | — | — | — | -669.4% | -98.2% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (226.79M) | (241.32M) | (198.64M) | (169.93M) | (52.49M) |
| Net Margin | — | — | — | -669.4% | -98.2% |
| EPS (Basic) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| EPS (Diluted) | (2.11) | (2.17) | (1.81) | (1.43) | (0.30) |
| Weighted Avg Shares | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
| Weighted Avg Shares (Diluted) | 110.78M | 108.27M | 109.53M | 118.56M | 172.21M |
Invivyd, Inc.
NASDAQ:IVVD
Intrinsic Alpha fair value
Locked
Current Price
$0.47
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.